News BMS adds to IBD pipeline with $1.9bn GentiBio deal Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face